GEN Exclusives

More »

GEN News Highlights

More »
Aug 1, 2012

Antibody Deal Combines Discovery with ADC Capabilities

  • Adimab and Mersana Therapeutics initiated a joint effort to offer integrated antibody discovery and antibody-drug conjugate (ADC) technologies. The alliance is built to offer pharmaceutical companies access to Adimab’s antibodies that have been specifically optimized for use in ADCs together with Mersana’s Fleximer polymer and broad array of customizable linkers for attaching diverse, potent payloads.

    “The flexibility in payloads, linkers, and drug loading enabled by Mersana’s Fleximer technology complements Adimab’s philosophy of tailoring drug development to the biology of the target of interest,” says Adimab CEO Tillman Gerngross. “With this deal, Adimab is further expanding its footprint beyond monoclonal antibody discovery. We view ADCs, as well as other aspects of antibody discovery such as bispecific formats, as important tools in the development of novel therapeutics.”

    “Together we can provide ADCs with increased likelihood of target selectivity and therapeutic efficacy,” adds Mersana CEO Nicholas Bacopoulos.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?